<DOC>
	<DOCNO>NCT00293826</DOCNO>
	<brief_summary>The purpose study determine AMG 108 combination methotrexate safe effective treatment rheumatoid arthritis .</brief_summary>
	<brief_title>A Multiple Dose Study Evaluate Subcutaneous AMG 108 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects active rheumatoid arthritis diagnose meeting ACR classification criterion least 6 month . Must take MTX consecutively &gt; /= 12 week stable dose methotrexate 1525 mg weekly least 4 week prior screen Receipt commercial experimental biologic therapy treatment inflammatory disease Presence serious infection Class IV rheumatoid arthritis Prior current history tuberculosis infection exposure Any DMARDs methotrexate within 6 week screen Pregnant nursing Receipt live vaccine within 3 month Felty 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>ACR criterion</keyword>
	<keyword>methotrexate</keyword>
	<keyword>DMARDs</keyword>
	<keyword>patient report outcome</keyword>
	<keyword>joint assessment</keyword>
</DOC>